Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer.
These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Key Highlights

– Report deliverables include an Excel-based forecast model
– Forecasts includes the 8MM
– Forecasts covers from 2024-2034
– GlobalData valued the Pancreatic cancer market in the 8MM at $2.2 billion in 2024 and expects the market to increase to $10.2 billion by 2034

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
In the 8MM, the number of diagnosed incident cases of pancreatic cancer will grow from 229,166 cases in 2024 to 283,540 cases by 2034.
Common Pancreatic Cancer market drivers across the 8MM include –
• This market growth will be driven by the market entry of novel pipeline agents in both the established and unexplored patient segments, in addition to the active label expansion of marketed agents to cover patients with early disease.
• During the 2024 base year, chemotherapies contributed the most to the pancreatic cancer market. By the end of the forecast period, immune checkpoint inhibitors and immunostimulants are projected to account for nearly half of the total market share across the 8MM.
• Market entrance of bispecific antibodies and pan-KRAS inhibitor will have a significant impact on the treatment landscape.
• Across the 8MM, the metastatic first, second, and third lines of therapy are expected to experience the fastest growth in the forecast period at a CAGR of 15.5–26.6%, compared to the 2.5–3.6% CAGR in early-stage neoadjuvant and adjuvant therapy.

Common barriers to market growth experienced across the 8MM include –
• Limited approved targeted therapy and poor clinical outcomes of immunotherapy are the two biggest obstacles for pancreatic cancer market growth.
• Many patients are diagnosed with advanced disease, and due to poor performance, do not reach beyond first-line therapy.
• Low patient population (BRCA1/2, PALB2, EGFR, MSI-H, NTRK, ROS1, KRAS, PD-1/PD-L1, and BRAF) is a major barrier to developing biomarker-based targeted therapy and market growth.

Scope

Overview of Pancreatic cancer, including epidemiology, symptoms, diagnosis, and disease management.

Annualized Pancreatic cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Pancreatic cancer therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Pancreatic cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.

Analysis of the current and future market competition in the global Pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Key Highlights

This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, and Japan).

The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.

Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Pancreatic Cancer market.

The base year of the sales forecast model is 2024, and the forecast period is 2024-2034.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Pancreatic cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Pancreatic cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Astellas
Ability Pharmaceuticals
Abraxis Bio
Akeso
Alligator Bioscience
Amgen
Arcus Biosciences
AstraZeneca
Autotelic
Bayer
BeOne
Biotech Bio
BMS
Bristol-Myers Squibb
Clovis
Daiichi Sankyo
Debiopharm
Eleison Pharmaceuticals
Eli Lilly
GSK
HUTCHMED
ImmunityBio
Ipsen
Jiangsu Hengrui Medicine
Kyowa
LadRx Corp
Loxo
Merck
Merus NV
Mirati
Novartis
Novocure
Oncotelic
Panavance Therapeutics
Panbela Therapeutics
Revolution Medicines
Roche
Sanofi
Sumitomo
Summit Therapeutics
Taiho
TME Therapeutics Inc
Yakult Honsha

Table of Contents

Abbreviations

Related Reports

Executive Summary

Disease Overview

Overview of Pancreatic Cancer

Pancreatic Cancer Market Strength, Weakness, Opportunity, and Threat Analysis

Epidemiology

Diagnosed Incident Cases Both Sexes

Age-Specific Diagnosed Incident Cases

Sex-Specific Diagnosed Incident Cases

Diagnosed Incident Cases by Type, Sex, Age

Diagnosed Incident Cases by Stage at Diagnosis

Diagnosed Incident Cases by Tumor Stage at Diagnosis

Diagnosed Incident Cases of Stage Ta Pancreatic Cancer by Grade

Diagnosed Incident Cases of Stage of Pancreatic Cancer by Broad Classification

Diagnosed Incident Cases of Stage of NMIBC by Risk Group

Diagnosed Incident Cases of Pancreatic Cancer by Mutations and Biomarkers

Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer

Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Tumor Stage

Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Broad Classification

Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Relapse or Recurrence

Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer by Treatment

Disease Management

Treatment Guidelines

Treatment Paradigm – First-Line Therapy in Non-Muscle Invasive Pancreatic Cancer

Treatment Paradigm – First-Line Therapy in Muscle Invasive Pancreatic Cancer

Treatment Paradigm – Locally Advanced/Metastatic Pancreatic Cancer

KOL Insight on the Pancreatic Cancer Treatment Algorithm

Unmet Needs and Opportunities

Unmet Needs in Pancreatic Cancer

Competitive Landscape Assessment

Pipeline Drugs Overview

Competitive Landscape Methodology

Competitive Assessment – Intravesical Delivered Therapies for NMIBC

Competitive Assessment – Gene Therapies for NMIBC

Competitive Assessment – Antibody-Drug Conjugates

Market Outlook

Pancreatic Cancer Market Forecast

Pancreatic Cancer Market Forecast by Class

Pancreatic Cancer Market Drivers and Barriers

Appendix

Primary Research: KOL Information

Sources Used and Not Used to Forecast Diagnosed Incident Cases

Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis

Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis

Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Pancreatic Cancer by Grade

Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification

Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group

Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers

Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases

Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence

Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment

Sources and Methodology

Epidemiological Forecast Insight

Strengths and Limitations

About the Authors

Bibliography

Contact Us

Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

  • Access a live Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.